Kancera is a leading brand in the development of a new class of medicines that target life-threatening diseases such as cancer and inflammation. With a focus on developing drug candidates that act through the fractalkine system, Kancera pioneers the creation of small-molecule inhibitors that precisely control both immune cells and cancer cells. Independent research groups have identified the fractalkine system as a critical factor in the severity of inflammation and cancer progression in humans.

Kancera stands out in the field, as it is at the forefront of developing these inhibitors. Their goal is to contribute to a normalized life and more effective healthcare. Kancera's team consists of highly skilled professionals with extensive experience in medical discoveries, product development, and clinical safety studies.

They partner with pharmaceutical companies to commercialize their patented assets after positive results from patient studies. With their ongoing efforts and dedication to innovation, Kancera aims to revolutionize the treatment of cancer and inflammation